Sorrento Therapeutics und mRNA
Seite 1 von 7 Neuester Beitrag: 19.12.22 23:55 | ||||
| Eröffnet am: | 18.08.21 12:33 | von: Meikel 1 2 . | Anzahl Beiträge: | 162 |
| Neuester Beitrag: | 19.12.22 23:55 | von: Bullish_Hope | Leser gesamt: | 40.647 |
| Forum: | Hot-Stocks | Leser heute: | 32 | |
| Bewertet mit: |  | |||
| Seite: < | 2 | 3 | 4 | 5 | 6 | 7 7 > | ||||
Das Scilex-Segment ist um seine nicht-opioiden Schmerzbehandlungsoperationen herum organisiert.
Ich eröffne dieses neue Forum um aktiv Themen um die aktuelle Entwicklung
von Sorrento Theraputics Inc. (SRNE) zu diskutieren und Informationen auszutauschen
August 09, 2021 14:39 ET | Source: Sorrento Therapeutics, Inc.
https://www.globenewswire.com/news-release/2021/...pment-Program.html
The presentation can be viewed at:
https://investors.sorrentotherapeutics.com/...entations/presentations
MACD Signal bricht aber von unten
leicht durch ...
es fehlen noch Infos...
über die aktuellen Entwicklungen..
Angehängte Grafik:
srne_chart_18082021.png (verkleinert auf 33%)
srne_chart_18082021.png (verkleinert auf 33%)
wirds spannend..
finance.yahoo.com/news/...rXl23SQf9EQrs30BTEbnDqBzmbk4p_Gy5nV
der Immunisierungseffizienz in den Lymphknoten
Sorrento Needle-Free Delivery Technology Designed to Maximize Immunization Efficiency
Lymph nodes are the primary organs for generating adaptive immune responses as dendritic cells activate T and B cells. Thus, delivering therapeutics directly
toward lymph nodes (versus most common method of delivery into muscle tissue or blood) presents an opportunity to potentially improve current vaccines.
Seite 12
https://investors.sorrentotherapeutics.com/...-4bf9-b935-7bb8c24fb39a
State-of-the-art cGMP antibody and cell therapy manufacturing facility located in San Diego, CA, initially designed to be a multi-product facility for the manufacture of bulk purified proteins and antibodies for use as therapeutics. The redesigned facility meets applicable cGMP requirements for manufacture of Investigational New Drugs, and now includes capabilities for cellular therapies.
https://sorrentotherapeutics.com/manufacturing/
2009
Founded
2013
Acquired Resiniferatoxin (RTX) assets via the acquisition of Sherrington Pharmaceuticals Inc.
Acquired Antibody Drug Conjugation (ADC) technologies via acquisition of Concortis Biosystems Corp.
2014
Out-licensed PD-L1 for Greater China market to Lee’s Pharm
2016
Formed ImmuneOncia JV with Yuhan Pharmaceuticals
Acquired ZTlido® via majority stake in Scilex Pharmaceuticals
Acquired Bioserv Corporation for cGMP manufacturing operations
Formed Levena Suzhou Biopharma Co. LTD for Antibody Drug Conjugation (ADC) services
2017
Acquired Oncolytic Virus platform via the acquisition of Virttu Biologics Limited
Formed Celularity with Celgene and United Therapeutics
2018
Acquired Sofusa® Lymphatic Delivery System from Kimberly-Clark
2019
Acquired Semnur Pharmaceuticals
Formed Scilex Holding to consolidate the merger of Scilex Pharma and Semnur Pharma
2020
Exclusively licensed Abivertinib from ACEA Therapeutics for all indications worldwide, excluding China
Exclusively licensed HP-LAMP diagnostic platform from Columbia University for the detection of coronaviruses and influenza viruses
Acquired SmartPharm Therapeutics
2021
Acquired ACEA Therapeutics
https://sorrentotherapeutics.com/who-we-are/history/
Zulassungsantrag der FDA für den Notfall (EUA) erwartet
COVISTIX (diagnostischer) Antigentest
FDA-Antrag auf Zulassung zur Notfallverwendung (EUA) eingereicht
COVITRACK – Platin (diagnostischer) Antikörpertest der nächsten Generation
In der Endfertigung und klinischen Prüfung
https://sorrentotherapeutics.com/research/pipeline/
https://clinicaltrials.gov/ct2/show/study/NCT04440007
Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate)
in Subjects Hospitalized With COVID-19 (SOC)
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) With Standard of Care Versus Standard of Care in Subjects Hospitalized With COVID-19
Actual Study Start Date : October 9, 2020
Estimated Primary Completion Date : May 5, 2021
Estimated Study Completion Date : July 2021
August 19, 2021 at 9:00 AM EDT
Download PDF
PALO ALTO, Calif., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Scilex Holding Company (SCILEX), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE), announced that, effective September 1, 2021, ZTlido® (lidocaine topical system) 1.8% has been added to multiple formularies, including two national PBMs (Pharmacy Benefit Managers), a national health plan and two regional health plans – thereby expanding coverage by up to 33 million lives. ZTlido (zee-tee-lie-doh) is indicated for relief of pain associated with post-herpetic neuralgia (PHN), also referred to as post-shingles pain.
“With this expansion, up to 65% of lives nationally have covered or better access to ZTlido, with a reduction in need for prior authorization,” said Jaisim Shah, President and Chief Executive Officer of Scilex Holding Company. “ZTlido provides fast and significant PHN pain relief that can be sustained over time – without the trade-offs associated with other widely used options, notably impaired cognition and weight gain (seen with gabapentinoids), and analgesic tolerance and risk of addiction (seen with opioids). 1-4 In fact, ZTlido can be used in combination to optimize gabapentinoids by delivering additive, remarkable pain relief without adding to systemic adverse events – and the combination has the potential to reduce the use of opioids.”1,5,6,*
However, not all lidocaine patch products are created equal. ZTlido 1.8% uses proprietary ZTech advanced technology to provide 9x greater bioavailability versus 5% lidocaine patch and superior adhesion proven in head-to-head studies, and while showering, bathing or exercising.7-12 This ensures that pain relief is delivered for the full treatment duration, without interrupting a patient’s routine.
ZTlido was approved by the U.S. Food and Drug Administration (FDA) in 2018 for relief of pain associated with post-herpetic neuralgia (PHN) in adults. Side effects of ZTlido include application site reactions such as, irritation, erythema, and pruritus.
Hier gibte es einige Katalysatoren für den Kurs, wenn alles so läuft wie geplant.
Viel Glück allen Investierten.
"Mehrere Produkte im Spätstadium der klinischen Entwicklung
für Schmerztherapie, Immunonkologie und COVID-19"
Angehängte Grafik:
seite_3_praesentation.jpg (verkleinert auf 43%)
seite_3_praesentation.jpg (verkleinert auf 43%)
18.03.22§ Jahr 2021 Ergebnisveröffentlichung (geplant)
16.05.22§ Q1 2022 Ergebnisveröffentlichung (geplant)
(Abivertinib-Maleat) bei Patienten, die mit COVID-19
ins Krankenhaus eingeliefert wurden
https://ichgcp.net/de/clinical-trials-registry/NCT04440007
ABIVERTINIB
Abivertinib is a novel small molecule tyrosine kinase inhibitor (TKI) that selectively targets both mutant forms of the epidermal growth factor receptor (EGFR) and Bruton’s tyrosine kinase (BTK) to treat Non-Small Cell Lung Cancer.
More than 600 patients have been treated with Abivertinib at different oral doses up to 300 mg bid in multiple trials through registration trial (NCT03856697) in patients with non-small cell lung cancer (NSCLC) and B cell malignancies (Phase 1) conducted in China. Favorable safety, tolerability and efficacy in patients with NSCLC or relapsed/refractory B-cell malignancies were demonstrated in the studies.
Abivertinib is also being tested as a potential treatment for cytokine storm associated with COVID-19 and as a potential treatment for cytokine release syndrome associated with CAR-T.
Aug. 19, 2021 5:06 PM ETSorrento Therapeutics, Inc. (SRNE)Dyadic International, Inc. (DYAI)By: Dulan Lokuwithana, SA News
https://seekingalpha.com/news/...eed_news_all&utm_medium=referral
August 19, 2021 16:21 ET | Source: Sorrento Therapeutics, Inc.
https://www.globenewswire.com/news-release/2021/...-Multiple-Maj.html